A Phase 2 interventional study of NBI-98854 and NBI-98854 in Tardive Dyskinesia, sponsored by Neurocrine Biosciences. Completed at 51 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-11-08.
Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one is the 6th largest by enrollment, is one of 2 that started in 2012, is one of 4 in phase 2, and was the 3rd registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 5
First in 2011; this study’s year is marked. 2 started in 2012.
This study's enrollment of 109 is above the median of 60 across 51 interventional studies indexed under Tardive Dyskinesia.
Median enrollment 101 across the 14 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 4 most frequent:
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
13 studies in Tardive Dyskinesia by Neurocrine Biosciences: 2 open now, 2 under way, none of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 13 studies in Tardive Dyskinesia by Neurocrine Biosciences, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2012, is one of 5 in phase 2, and was the 3rd registered.
Neurocrine Biosciences’s Tardive Dyskinesia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Neurocrine Biosciences’s 13 in Tardive Dyskinesia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses (50 and 100 mg) of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of two doses (50 and 100 mg) of NBI-98854 administered once daily for up to 2 weeks. The study will also allow for an evaluation of the efficacy of NBI-98854 50 mg once daily for up to 6 weeks and the safety and tolerability of NBI 98854 50 mg once daily for up to 12 weeks.
The double-blind placebo-controlled treatment period the study has three arms:
At the end of the 6-week placebo-controlled double-blind treatment period, subjects will continue in the study for an additional 6-week open-label period where all subjects who have completed the double-blind treatment period will receive NBI-98854 50 mg once daily. Two and four weeks after the last dose of study drug, follow-up assessments will be performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NBI-98854 50 mg administered as two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
Drug: NBI-98854
NBI-98854 100 mg administered as two (2) 50 mg capsules taken every morning between 7:00am - 10:00am for 2 weeks. After 2 weeks, NBI-98854 50 mg administered by two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for remaining 4 weeks.
Drug: NBI-98854
Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
Drug: Placebo
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6
The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity. The primary efficacy endpoint was the change from baseline in the AIMS dyskinesia total score at Week 6 between the pooled NBI-98854 50+100 mg group and placebo group analyzed using the ANCOVA model (LOCF, ITT analysis set).
Time frame: Baseline and Week 6
Clinical Global Impression - Global Improvement of TD (CGI-TD)
Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse). The ANOVA analysis of CGI-TD was conducted for the pooled NBI-98854 50+100 mg group and placebo group.
Time frame: Week 6
Clinical Global Impression - Global Improvement of TD (CGI-TD) at Week 2
Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).
Time frame: Week 2
This study enrolled patients with a clinical diagnosis of schizophrenia or schizoaffective disorder with moderate or severe tardive dyskinesia (TD) from 35 centers in the United States and Puerto Rico. The last patient completed in October 2013.
| Milestone | Double-Blind Placebo, Then Open-Label 50mg | Double-Blind 50mg, Then Open-Label 50mg | Double-Blind 100mg/50mg, Then Open-Label 50mg |
|---|---|---|---|
| Started | 54 | 28 | 27 |
| Completed | 47 | 25 | 21 |
| Not completed | 7 | 3 | 6 |
| Withdrew: Adverse event | 1 | 0 | 1 |
| Withdrew: Non-compliance | 1 | 2 | 3 |
| Withdrew: Withdrawal by subject | 4 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Milestone | Double-Blind Placebo, Then Open-Label 50mg | Double-Blind 50mg, Then Open-Label 50mg | Double-Blind 100mg/50mg, Then Open-Label 50mg |
|---|---|---|---|
| Started | 47 | 25 | 21 |
| Completed | 42 | 22 | 17 |
| Not completed | 5 | 3 | 4 |
| Withdrew: Adverse event | 4 | 1 | 1 |
| Withdrew: Non-compliance | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Milestone | Double-Blind Placebo, Then Open-Label 50mg | Double-Blind 50mg, Then Open-Label 50mg | Double-Blind 100mg/50mg, Then Open-Label 50mg |
|---|---|---|---|
| Started | 42 | 22 | 17 |
| Completed | 42 | 21 | 17 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity. The primary efficacy endpoint was the change from baseline in the AIMS dyskinesia total score at Week 6 between the pooled NBI-98854 50+100 mg group and placebo group analyzed using the ANCOVA model (LOCF, ITT analysis set).
| units on a scale | Placebo | All Valbenazine |
|---|---|---|
| Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6 | -2.5 ± 0.7 | -3.3 ± 0.7 |
Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse). The ANOVA analysis of CGI-TD was conducted for the pooled NBI-98854 50+100 mg group and placebo group.
| units on a scale | Placebo | Valbenazine 50mg and Valbenazine 100mg Then 50mg |
|---|---|---|
| Clinical Global Impression - Global Improvement of TD (CGI-TD) | 3.2 ± 0.1 | 3.3 ± 0.1 |
Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).
| units on a scale | Placebo | Valbenazine 50mg | Valbenazine 100mg |
|---|---|---|---|
| Clinical Global Impression - Global Improvement of TD (CGI-TD) at Week 2 | 3.6 ± 0.1 | 3.3 ± 0.2 | 3.2 ± 0.2 |
Collected over Up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind 50mg | 0/28 (0%) | 2/28 (7.1%) | 4/28 (14.3%) |
| Double-Blind 100mg/50mg | 0/27 (0%) | 0/27 (0%) | 3/27 (11.1%) |
| Double-Blind Placebo | 0/54 (0%) | 1/54 (1.9%) | 2/54 (3.7%) |
| Open-Label 50mg | 0/93 (0%) | 3/93 (3.2%) | 5/93 (5.4%) |
| Follow-Up | 0/80 (0%) | 0/80 (0%) | 1/80 (1.3%) |
| Event | Double-Blind 50mg | Double-Blind 100mg/50mg | Double-Blind Placebo | Open-Label 50mg | Follow-Up |
|---|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 1/28 | 0/27 | 0/54 | 0/93 | 0/80 |
| Chest painGeneral disorders | 1/28 | 0/27 | 0/54 | 0/93 | 0/80 |
| Schizophrenia, paranoid typePsychiatric disorders | 0/28 | 0/27 | 1/54 | 0/93 | 0/80 |
| Schizoaffective disorderPsychiatric disorders | 0/28 | 0/27 | 0/54 | 1/93 | 0/80 |
| BronchitisInfections and infestations | 0/28 | 0/27 | 0/54 | 1/93 | 0/80 |
| SchizophreniaPsychiatric disorders | 0/28 | 0/27 | 0/54 | 1/93 | 0/80 |
| Suicidal ideationPsychiatric disorders | 0/28 | 0/27 | 0/54 | 1/93 | 0/80 |
| Event | Double-Blind 50mg | Double-Blind 100mg/50mg | Double-Blind Placebo | Open-Label 50mg | Follow-Up |
|---|---|---|---|---|---|
| FatigueGeneral disorders | 0/28 | 2/27 | 0/54 | 0/93 | 0/80 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/28 | 0/27 | 0/54 | 0/93 | 1/80 |
| SomnolenceNervous system disorders | 2/28 | 1/27 | 0/54 | 0/93 | 0/80 |
| Urinary tract infectionInfections and infestations | 0/28 | 1/27 | 2/54 | 5/93 | 0/80 |
Safety analysis set (all randomized subjects who received at least 1 dose of study drug).
| Age, Continuous(years) | Double-Blind Placebo, Then Open-Label 50mg | Double-Blind 50mg, Then Open-Label 50mg | Double-Blind 100mg/50mg, Then Open-Label 50mg | Total |
|---|---|---|---|---|
| Mean | 54.5 (27 to 76) | 55.5 (42 to 72) | 55.6 (28 to 77) | 55.0 (27 to 77) |
| Sex: Female, Male(Participants) | Double-Blind Placebo, Then Open-Label 50mg | Double-Blind 50mg, Then Open-Label 50mg | Double-Blind 100mg/50mg, Then Open-Label 50mg | Total |
|---|---|---|---|---|
| Female | 20 | 8 | 9 | 37 |
| Male | 34 | 20 | 18 | 72 |
| Race/Ethnicity, Customized(Participants) | Double-Blind Placebo, Then Open-Label 50mg | Double-Blind 50mg, Then Open-Label 50mg | Double-Blind 100mg/50mg, Then Open-Label 50mg | Total |
|---|---|---|---|---|
| Black or African American | 29 | 12 | 7 | 48 |
| White | 23 | 15 | 19 | 57 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Other | 0 | 1 | 0 | 1 |
| American Indian or Alaska Native, Black | 1 | 0 | 1 | 2 |
| Body Mass Index(kg/m^2) | Double-Blind Placebo, Then Open-Label 50mg | Double-Blind 50mg, Then Open-Label 50mg | Double-Blind 100mg/50mg, Then Open-Label 50mg | Total |
|---|---|---|---|---|
| Mean | 28.71 (19.2 to 44.2) | 28.85 (18.5 to 42.6) | 26.39 (14.1 to 37.8) | 28.17 (14.1 to 44.2) |
| Age at Schizophrenia/Schizoaffective Disorder Diagnosis(years) | Double-Blind Placebo, Then Open-Label 50mg | Double-Blind 50mg, Then Open-Label 50mg | Double-Blind 100mg/50mg, Then Open-Label 50mg | Total |
|---|---|---|---|---|
| Mean | 29.4 (10 to 68) | 29.7 (16 to 66) | 30.4 (17 to 66) | 29.7 (10 to 68) |
| Age at TD Diagnosis(years) | Double-Blind Placebo, Then Open-Label 50mg | Double-Blind 50mg, Then Open-Label 50mg | Double-Blind 100mg/50mg, Then Open-Label 50mg | Total |
|---|---|---|---|---|
| Mean | 46.9 (16 to 73) | 48.5 (37 to 67) | 47.5 (22 to 73) | 47.5 (16 to 73) |
| BPRS Total Score(units on a scale) | Double-Blind Placebo, Then Open-Label 50mg | Double-Blind 50mg, Then Open-Label 50mg | Double-Blind 100mg/50mg, Then Open-Label 50mg | Total |
|---|---|---|---|---|
| Mean | 33.8 (20 to 48) | 32.6 (22 to 49) | 33.0 (21 to 49) | 33.3 (20 to 49) |
| Baseline AIMS Total Dyskinesia Score(units on a scale) | Double-Blind Placebo, Then Open-Label 50mg | Double-Blind 50mg, Then Open-Label 50mg | Double-Blind 100mg/50mg, Then Open-Label 50mg | Total |
|---|---|---|---|---|
| Mean | 15.3 ± 4.4 | 14.6 ± 5.9 | 14.6 ± 4.7 | 15.0 ± 4.8 |
The record gives a start of Sep 2012, a primary completion of Sep 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2017, 4 years 2 months after primary completion. A results delay was requested in Oct 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valbenazine